This excerpt taken from the SNY 20-F filed Apr 11, 2005.
At the discovery stage:
A partnership initiated in 1999, with Genfit (Lille, France) allows studies of novel biological targets in the general area of atherosclerosis and within an exclusive alliance in the PPAR ligands in the fields of type 2 diabetes, metabolic syndrome, multiple sclerosis and inflammation.
An alliance was formed in 2000 with Millennium (Cambridge, Massachusetts, U.S.) to bolster our inflammation portfolio by validating novel biological targets and rapidly progressing high-value compounds into the development stage.
A partnership, started in 1997, with Cerep (Rueil-Malmaison, France) aims at extending our general chemical library and screening the new exclusive synthesized libraries on novel biological targets.
A few global licenses have been acquired from GeneLogic (Gaithesburg, Maryland, U.S.) to enable the implementation of toxicogenomic technologies and to access expression profiling databases.
A collaboration with Astex (Cambridge, UK) has been put in place to measure the binding properties of proprietary compounds with apo P-450 enzymes in order to select the best potential drug candidates.
An agreement with Amphora (Durham, North Carolina, U.S.) was initiated in 2004 in order to profile and screen dedicated libraries using microfluid-based compound profiling.
An alliance started in 2003 with Immunogen (Cambridge, Massachusetts, U.S.) aims at identifying and developing naked antibodies or immunoconjugates (monoclonal antibodies coupled to an anticancer compound) in the area of oncology, and also covers a technology transfer and a license agreement on three identified products.
A global license and research collaboration has been set with Coley (Wellesley, Massachusetts, U.S.) in the area of CpG oligonucleotides acting as immunomodulators, to address diseases in the area of asthma, allergic rhinitis, and chronic obstructive pulmonary diseases.
A long-standing research collaboration with Mitsubishi Pharmaceutical Corp (Tokyo, Japan) to identify and develop novel agents in the area of neurodegenerative diseases is being extended.
Within the Impact Malaria program, three research alliances have been established. Ferroquine, co-developed with the Université Scientifique et Technique (Lille, France), is currently in Phase I.